Overview

  • Product name
    Doxorubicin hydrochloride
  • Description
    Topoisomerase II inhibitor. Antibiotic with cytotoxic actions.
  • Alternative names
    • Adriamycin
  • Biological description

    Topoisomerase II inhibitor (IC50 = 100 nM, Hep3B cells). DNA intercalator that prevents synthesis of nucleic acid. Induces apoptosis.

  • Purity
    > 98%

Properties

Images

  • All lanes : Anti-DR5 antibody [EPR22276] (ab230969) at 1/1000 dilution

    Lane 1 : Untreated HCT116 (human colorectal carcinoma epithelial cell), whole cell lysate
    Lane 2 : HCT116 treated with 0.5 µM doxorubicin (ab120629) for 24 hours, whole cell lysate

    Lysates/proteins at 20 µg per lane.

    Secondary
    All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution

    Exposure time: 3 minutes


    The molecular weight observed is consistent with what has been described in the literature, the 40kDa band is a cleaved form (PMID: 20515924, 16297203).

    Blocking/Dilution buffer: 5% NFDM/TBST.

References

This product has been referenced in:
  • Sauter KA  et al. Doxorubicin and daunorubicin induce processing and release of interleukin-1ß through activation of the NLRP3 inflammasome. Cancer Biol Ther 11:1008-16 (2011). Read more (PubMed: 21464611) »
  • Lal S  et al. Pharmacogenetics of target genes across doxorubicin disposition pathway: a review. Curr Drug Metab 11:115-28 (2010). Read more (PubMed: 20302569) »
  • Gieseler F  et al. Cytotoxicity of anthracyclines: correlation with cellular uptake, intracellular distribution and DNA binding. Ann Hematol 69 Suppl 1:S13-7 (1994). Read more (PubMed: 8061108) »
See all 2 Publications for this product

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab120629.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE, NOT FOR USE IN HUMANS"

Sign up